KR970705416A - 종양질병 치료용 생백신(live vaccine for the treatment of tumour diseases) - Google Patents

종양질병 치료용 생백신(live vaccine for the treatment of tumour diseases)

Info

Publication number
KR970705416A
KR970705416A KR1019970701175A KR19970701175A KR970705416A KR 970705416 A KR970705416 A KR 970705416A KR 1019970701175 A KR1019970701175 A KR 1019970701175A KR 19970701175 A KR19970701175 A KR 19970701175A KR 970705416 A KR970705416 A KR 970705416A
Authority
KR
South Korea
Prior art keywords
gene
live vaccine
cells
vaccine
tumor
Prior art date
Application number
KR1019970701175A
Other languages
English (en)
Inventor
토마스 블란켄슈타인
소피 카요-페쥬토
Original Assignee
간텐 데. 죠스트 에.
막스-델부릭-센트럼 퓌어 몰레쿨라레 메디친
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 간텐 데. 죠스트 에., 막스-델부릭-센트럼 퓌어 몰레쿨라레 메디친 filed Critical 간텐 데. 죠스트 에.
Publication of KR970705416A publication Critical patent/KR970705416A/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001136—Cytokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5406—IL-4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5418—IL-7
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70532—B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5152—Tumor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/027—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a retrovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

본 발명은 유전공학 기술에 의해 제조된 3개의 부가적인 유전자들을 포함하는 생 종양-세포 백신의 제조 및 용도에 관한 것이다; a) 면역자극성 활성을 갖는 세포-표면 단백질을 암호하는 유전자, b) 사이토킨 유전자 및 c) 티미딘 카이나제 유전자. 본 발명의 응용 분야는 의약 및 유전공학 분야이다. 제시된 생백신은 그 효과가 상승적인 항-종양 반응이 면역자극성 활성을 암호하는 유전자들의 다중 전이에 의해 유도된다는 사실에 기인한다. 이것은 백신세포들의 확실한 거부를 초래하고, 증식할 수 있는 세포들을 백신으로 주입할 수 있게 한다. 부가적인 안전 마커로, 백신 세포들에 상기 백신세포들을 생체내에서 선택적으로 치사시킬수 있는 티미딘 카이나제 유전자를 부여한다. 면역자극성 활성을 갖는 유전자들의 조합적인 발현은 종래 종양-세포 백신들과 비교해서 백신 효과를 개선시키며, 그리고 생 종양-세포 백신은 증식할수 없는 세포들로 이루어진 백신 보다 더 효과적이다. 상기 백신은 암환자의 유전자적 치료용으로 사용될 것이다.

Description

종양질병 치료용 생백신(LIVE VACCINE FOR THE TREATMENT OF TUMOUR DISEASES)
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (15)

  1. 사이토킨 유전자 및 면역자극성 막단백질 유전자로 이루어진 유전자-변형된 종양세포들을 가지는 종양질병 치료용 생백신.
  2. 제1항에 있어서, 상기 종양세포가 하나 또는 여러개의 자살유전자를 더 포함하는 생백신.
  3. 제1항 또는 제2항에 있어서, 상기 종양세포가 사이토킨 유전자, 면역자극성 막단백질 유전자 및 자살유전자를 포함하는 생백신.
  4. 제1항 내지 제3항 중 어느 한 항에 있어서, 증식할 수 있는 자가조직 또는 동종조직 종양세포들이 종양세포로 사용되는 생백신.
  5. 제1항 내지 제4항 중 어느 한 항에 있어서, 상기 사이토킨 유전자가 트랜스팩션을 통해 얻어진 생백신.
  6. 제1항 내지 제5항에 있어서, 사이토킨이 면역세포들의 분화, 증식 및 활성을 유도하는 물질인 생백신.
  7. 제1항 내지 제6항에 있어서, 상기 종양세포들이 사이토킨 유전자로 인터루킨 2, 인터루킨 4, 인터루킨 7, 인터페론 또는 과립구 대식세포 콜로니 자극인자(GM-CSF)에 대한 유전자로 이루어진 생백신.
  8. 제1항 내지 제7항에 있어서, 상기 면역자극성 막 유전자가 T세포들을 활성화시키는 단백질들을 암호하는 생백신.
  9. 제1항, 제3항 및 제8항에 있어서, 상기 면역자극성 막단맥질 유전자가 T세포들을 상호자극적인 분자B7 유전자인 생백신.
  10. 제1항 내지 제3항에 있어서, 자살유전자가 활성물질을 독성 생성물로 전환시키는 물질인 생백신.
  11. 제1항 내지 제3항 또는 제10항 중 어느 한 항에 있어서, 상기 자살유전자가 허피스 심플렉스 바이러스의 티미딘 카이나제 유전자(HSV-TK) 또는 사이토신 디아미나제 유전자인 생백신.
  12. 자가조직 또는 동종조직 시스템에서의 제1항 내지 제11항 중 어느 한 항에 청구된 생백신 제조방법.
  13. 치료제로 사용되는 제1항 내지 제11항 중 어느 한 항에 청구된 생백신.
  14. 종양질병 치료를 위한 제1항 내지 제11항 중 어느 한 항에 청구된 생백신의 용도.
  15. 종양질병 치료를 위한 제1항 내지 제11항 중 어느 한 항에 청구된 생백신의 제조방법.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019970701175A 1994-08-24 1995-08-18 종양질병 치료용 생백신(live vaccine for the treatment of tumour diseases) KR970705416A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DEP4431401.9 1994-08-24
DE4431401A DE4431401A1 (de) 1994-08-24 1994-08-24 Lebendvakzine gegen Tumorerkrankungen
PCT/DE1995/001164 WO1996005866A2 (de) 1994-08-24 1995-08-18 Lebendvakzine zur behandlung von tumorerkrankungen

Publications (1)

Publication Number Publication Date
KR970705416A true KR970705416A (ko) 1997-10-09

Family

ID=6527332

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019970701175A KR970705416A (ko) 1994-08-24 1995-08-18 종양질병 치료용 생백신(live vaccine for the treatment of tumour diseases)

Country Status (13)

Country Link
US (1) US6039941A (ko)
EP (1) EP0777499B1 (ko)
JP (1) JP2975117B2 (ko)
KR (1) KR970705416A (ko)
AT (1) ATE228016T1 (ko)
AU (1) AU688101B2 (ko)
BR (1) BR9508765A (ko)
CA (1) CA2198234A1 (ko)
DE (3) DE4431401A1 (ko)
DK (1) DK0777499T3 (ko)
ES (1) ES2187568T3 (ko)
PT (1) PT777499E (ko)
WO (1) WO1996005866A2 (ko)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7361332B2 (en) 1995-03-17 2008-04-22 The Regents Of The University Of California Treating tumors using implants comprising combinations of allogeneic cells
US5952221A (en) * 1996-03-06 1999-09-14 Avigen, Inc. Adeno-associated virus vectors comprising a first and second nucleic acid sequence
DE19626830A1 (de) * 1996-07-04 1998-01-08 Max Delbrueck Centrum Konditionales Immortalisationsverfahren für humane Tumorzellen zur Herstellung einer Vakzine
US6277368B1 (en) 1996-07-25 2001-08-21 The Regents Of The University Of California Cancer immunotherapy using autologous tumor cells combined with cells expressing a membrane cytokine
JP2001509135A (ja) 1996-10-11 2001-07-10 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 混合リンパ球と組み合わせた腫瘍細胞を用いるガン免疫療法
AUPQ755300A0 (en) 2000-05-17 2000-06-08 Monash University Immune potentiating compositions
AU785241B2 (en) * 2000-05-17 2006-11-23 Cancure Limited Immune potentiating compositions
AU2003281200A1 (en) * 2002-07-03 2004-01-23 Tasuku Honjo Immunopotentiating compositions
GB0223696D0 (en) * 2002-10-14 2002-11-20 Ml Lab Plc Improved immunotherapy
JP2006096663A (ja) * 2002-10-17 2006-04-13 Sangaku Renkei Kiko Kyushu:Kk 癌遺伝子ワクチン
GB0227989D0 (en) * 2002-12-02 2003-01-08 Imp College Innovations Ltd Chimaeric molecules
US20130052215A9 (en) 2003-09-26 2013-02-28 Eckhard Podack Tumor vaccine
JP2007506764A (ja) * 2003-09-26 2007-03-22 ユニバーシティ オブ マイアミ 腫瘍ワクチン
BRPI0418157A (pt) * 2003-12-30 2007-04-17 Mologen Ag terapêutica de tumores alogênicos
EA200700598A1 (ru) 2007-03-07 2007-12-28 Петр Генриевич ЛОХОВ Противоопухолевая вакцина, способ получения противоопухолевой вакцины и способ проведения противоопухолевой иммунотерапии
US8741315B2 (en) 2007-09-12 2014-06-03 Yeda Research And Development Co. Ltd. Methods of treating tumors in immune-privileged sites
RU2407789C2 (ru) * 2008-07-25 2010-12-27 Виктор Владимирович Кешелава Способ получения живой клеточной вакцины для профилактики рака молочных желез
EA011421B1 (ru) * 2008-08-26 2009-02-27 Петр Генриевич ЛОХОВ Способ получения противоопухолевой вакцины
CN111743884A (zh) * 2019-03-26 2020-10-09 深圳先进技术研究院 苄丝肼或其衍生物的用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI91713C (fi) * 1992-04-23 1994-08-10 Axidental Oy Uusia bioaktiivisia pinnotteita ja niiden valmistus ja käyttö
CA2134763A1 (en) * 1992-05-01 1993-11-11 Kenneth W. Culver Bystander effect tumoricidal therapy
WO1994004196A1 (en) * 1992-08-14 1994-03-03 Imperial Cancer Research Technology Limited Tumour therapy

Also Published As

Publication number Publication date
ES2187568T3 (es) 2003-06-16
US6039941A (en) 2000-03-21
MX9701384A (es) 1998-03-31
DE4431401A1 (de) 1996-02-29
EP0777499B1 (de) 2002-11-20
AU3253195A (en) 1996-03-14
WO1996005866A3 (de) 1996-04-11
CA2198234A1 (en) 1996-02-29
PT777499E (pt) 2003-03-31
DK0777499T3 (da) 2003-03-17
DE59510466D1 (de) 2003-01-02
JPH10505339A (ja) 1998-05-26
JP2975117B2 (ja) 1999-11-10
EP0777499A1 (de) 1997-06-11
BR9508765A (pt) 1997-11-11
AU688101B2 (en) 1998-03-05
ATE228016T1 (de) 2002-12-15
WO1996005866A2 (de) 1996-02-29
DE19580890D2 (de) 1997-06-19

Similar Documents

Publication Publication Date Title
KR970705416A (ko) 종양질병 치료용 생백신(live vaccine for the treatment of tumour diseases)
Restifo Building better vaccines: how apoptotic cell death can induce inflammation and activate innate and adaptive immunity
Ren et al. Immunogene therapy of recurrent glioblastoma multiforme with a liposomally encapsulated replication-incompetent Semliki forest virus vector carrying the human interleukin-12 gene–a phase I/II clinical protocol
Rakhmilevich et al. Gene gun-mediated IL-12 gene therapy induces antitumor effects in the absence of toxicity: a direct comparison with systemic IL-12 protein therapy
Chen et al. Adaptive and innate immune responses to gene transfer vectors: role of cytokines and chemokines in vector function
Li et al. Cytokine and immuno-gene therapy for solid tumors
Ritter et al. Stimulatory and inhibitory action of cytokines on the regulation of hCMV-IE promoter activity in human endothelial cells
Barnard et al. Expression of FMS-like tyrosine kinase 3 ligand by oncolytic herpes simplex virus type I prolongs survival in mice bearing established syngeneic intracranial malignant glioma
Loskog Immunostimulatory gene therapy using oncolytic viruses as vehicles
Chuang et al. Electroporation‐mediated IL‐12 gene therapy in a transplantable canine cancer model
WO2018137643A1 (zh) 溶瘤病毒作为用于治疗肿瘤和/或癌症的免疫刺激剂的应用
Xiao et al. Local administration of TLR ligands rescues the function of tumor-infiltrating CD8 T cells and enhances the antitumor effect of lentivector immunization
Voronov et al. Antitumor and immunotherapeutic effects of activated invasive T lymphoma cells that display short-term interleukin 1α expression
Simovic et al. Mechanistic insights into the oncolytic activity of vesicular stomatitis virus in cancer immunotherapy
Mastrangelo et al. Virotherapy clinical trials for regional disease: in situ immune modulation using recombinant poxvirus vectors
Cao et al. Adenovirus-mediated GM-CSF gene and cytosine deaminase gene transfer followed by 5-fluorocytosine administration elicit more potent antitumor response in tumor-bearing mice
Zhang et al. An adenoviral vector expressing functional heterogeneous proteins herpes simplex viral thymidine kinase and human interleukin-2 has enhanced in vivo antitumor activity against medullary thyroid carcinoma.
Xie et al. The advances of adjuvants in mRNA vaccines
Podhajcer et al. Cytokine gene transfer for cancer therapy
Gillio Tos et al. Retroviral vector-mediated transfer of the tumor necrosis factor alpha gene into human cancer cells restores an apoptotic cell death program and induces a bystander-killing effect
Kokate A systematic overview of cancer immunotherapy: an emerging therapy
Ajiki et al. Long-lasting gene expression by particle-mediated intramuscular transfection modified with bupivacaine: combinatorial gene therapy with IL-12 and IL-18 cDNA against rat sarcoma at a distant site
Siapati et al. Improved antitumour immunity in murine neuroblastoma using a combination of IL-2 and IL-12
Eguchi et al. Interferon-α and interleukin-12 gene therapy of cancer: interferon-α induces tumor-specific immune responses while interleukin-12 stimulates non-specific killing
JPH06504450A (ja) ヒトあるいは動物有機体を措置するための細胞組成物

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E601 Decision to refuse application